Final overall survival and the association of pathological outcomes with event-free survival in MATTERHORN: A randomised, phase 3 study of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel in resectable gastric / gastroesophageal junction adenocarcinoma

Experts discuss tailored approaches to neoadjuvant therapy for esophageal and G-junction cancers, emphasizing the importance of multidisciplinary care.

Explore the evolving landscape of cancer treatment strategies, focusing on guideline-based management and the impact of multimodal approaches on patient outcomes.

Experts discuss tailored approaches to neoadjuvant therapy for esophageal and gastroesophageal junction cancers, emphasizing multidisciplinary care and surgical precision.

Experts discuss the challenges and strategies in managing patients with inadequate responses to preoperative cancer treatments, emphasizing the need for clinical trials.

A panel of experts gathered to discuss results from the MATTERHORN trial assessing durvalumab plus FLOT in gastric/GEJ cancer.

Experts discuss the challenges and strategies in managing patients with inadequate responses to preoperative cancer treatments, emphasizing the need for clinical trials.

Doctor Fontaine discusses the importance of patient selection for preoperative chemotherapy and the effectiveness of immune checkpoint inhibitors in surgery outcomes.

Experts discuss the significance of event-free survival and overall survival in cancer trials, emphasizing the importance of patient quality of life.

Experts discuss the significance of event-free survival and overall survival in cancer trials, emphasizing patient quality of life and treatment decisions.

Experts discuss the importance of PD-L1 testing in treatment decisions for gastric cancer, emphasizing personalized approaches and improved patient outcomes.

Oncologists discuss the significance of PCR and MPR rates in patient counseling, emphasizing treatment benefits and survival outcomes.

Experts discuss the strengths and limitations of the Matterhorn study, highlighting advancements in immunotherapy for upper GI cancer and future research directions.

Explore the complexities of managing a Stage 3 gastric adenocarcinoma case, focusing on surgical options and perioperative treatment strategies.

Experts discuss the management of immune-mediated side effects in perioperative cancer treatment, emphasizing patient care and monitoring strategies.

Discover how specialized cancer care, including nurse navigators and telehealth, enhances patient outcomes and quality of life post-treatment.